Ming Jiang
YOU?
Author Swipe
View article: TDP-43: unveiling the hidden key to cellular fate decisions
TDP-43: unveiling the hidden key to cellular fate decisions Open
TDP-43, a multifaceted RNA-binding protein (RBP), has emerged as a key regulator in neurodegenerative diseases. Yet, its underlying mechanisms of action across other diseases remain unclear. This review covers TDP-43’s structural domains, …
View article: Uncertainty-Aware Collaborative System of Large and Small Models for Multimodal Sentiment Analysis
Uncertainty-Aware Collaborative System of Large and Small Models for Multimodal Sentiment Analysis Open
The advent of Multimodal Large Language Models (MLLMs) has significantly advanced the state-of-the-art in multimodal machine learning, yet their substantial computational demands present a critical barrier to real-world deployment. Convers…
View article: CRISPR/Cas12a-Based Biosensing: Advances in Mechanisms and Applications for Nucleic Acid Detection
CRISPR/Cas12a-Based Biosensing: Advances in Mechanisms and Applications for Nucleic Acid Detection Open
Nucleic acid detection technology is crucial for molecular diagnosis. The advent of CRISPR/Cas12a-based nucleic acid detection has considerably broadened its scope, from the identification of infectious disease-causing microorganisms to th…
View article: Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial
Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial Open
Background Pegylated liposomal doxorubicin (PLD) was shown to have comparable efficacy to doxorubicin, with significantly reduced cardiotoxicity. This study evaluated the cardiotoxicity and efficacy of the PLD-based regimen compared with t…
View article: D.5 Efgartigimod treatment in participants with anti-acetylcholine receptor seronegative generalized myasthenia Myasthenia Gravis clinical studies
D.5 Efgartigimod treatment in participants with anti-acetylcholine receptor seronegative generalized myasthenia Myasthenia Gravis clinical studies Open
Background: Antibodies directed against acetylcholine receptor (AChR) are absent in approximately 15% of patients with gMG. Approved treatment options represent an unmet need in the AChR-antibody (Ab)- gMG population. Efgartigimod is an im…
View article: The gut microbiota in mice with erythropoietin—induced abdominal aortic aneurysm
The gut microbiota in mice with erythropoietin—induced abdominal aortic aneurysm Open
Background In recent years, a novel animal abdominal aortic aneurysm (AAA) model was established by administering erythropoietin (EPO) to wild-type (WT) mice. However, the influence of EPO on the murine fecal microbiota remains uninvestiga…
View article: Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities
Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities Open
Cdc2‐like kinase 4 (Clk4), a key member of the CMGC kinase family, plays a crucial role in alternative splicing, which profoundly influences various physiological processes, including cellular signaling, proliferation, and survival. Its in…
View article: Unraveling the ROS-Inflammation-Immune Balance: A New Perspective on Aging and Disease
Unraveling the ROS-Inflammation-Immune Balance: A New Perspective on Aging and Disease Open
Increased entropy is a common cause of disease and aging. Lifespan entropy is the overall increase in disorder caused by a person over their lifetime. Aging leads to the excessive production of reactive oxygen species (ROS), which damage t…
View article: A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment Open
Background cGvHD is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. CSF-1R-driven macrophage signaling plays a critical role in fibrosis, which is a hallmark of cGvHD. Thus, blocking t…
View article: An Immune‐Enhancing Injectable Hydrogel Loaded with Esketamine and DDP Promotes Painless Immunochemotherapy to Inhibit Breast Cancer Growth
An Immune‐Enhancing Injectable Hydrogel Loaded with Esketamine and DDP Promotes Painless Immunochemotherapy to Inhibit Breast Cancer Growth Open
Chemotherapy is the cornerstone of triple‐negative breast cancer. The poor effectiveness and severe neuropathic pain caused by it have a significant impact on the immune system. Studies confirmed that immune cells in the tumor microenviron…
View article: Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial
Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial Open
Objective To determine whether a single low dose of esketamine administered after childbirth reduces postpartum depression in mothers with prenatal depression. Design Randomised, double blind, placebo controlled trial with two parallel arm…
View article: Whole-exome sequencing identifies a CD38 variant in a Chinese family with Hodgkin’s lymphoma
Whole-exome sequencing identifies a CD38 variant in a Chinese family with Hodgkin’s lymphoma Open
Hodgkin’s lymphoma (HL) exhibits genetic susceptibility, but little is known about the pathogenic genes associated with the disease. Here, we present a case of two siblings from a consanguineous Chinese family who were both diagnosed with …
View article: Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases Open
Background Efgartigimod is a first-in-class, human immunoglobulin-G (IgG) Fc fragment that inhibits the neonatal Fc receptor (FcRn) and outcompetes endogenous IgG binding. FcRn inhibition by efgartigimod is a rational therapeutic option fo…
View article: PB1334 Safety Profile of Efgartigimod from Clinical Trials in Participants with Immunoglobulin G-Mediated Autoimmune Diseases
PB1334 Safety Profile of Efgartigimod from Clinical Trials in Participants with Immunoglobulin G-Mediated Autoimmune Diseases Open
Background: There is evidence that patients with Immune Thrombocytopenia (ITP) are at increased risk of thromboembolism (TE).The association between clinical and treatment -related factors with thrombosis remain controversial.Aims: To eval…
View article: Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment
Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment Open
Background Intracranial metastasis that failed standard systematic treatment is common in advanced non-small cell lung cancer (NSCLC), contributing significantly to morbidity and mortality. The aim of this study was to evaluate the efficac…
View article: P.045 Safety profile overview of Efgartigimod Clinical Trials in participants with diverse Diverse IgG-Mediated Autoimmune Diseases
P.045 Safety profile overview of Efgartigimod Clinical Trials in participants with diverse Diverse IgG-Mediated Autoimmune Diseases Open
Background: Efgartigimod is a human IgG1 antibody Fc-fragment that reduces IgG autoantibody levels through FcRn blockade. This study reports safety of efgartigimod across IgG-mediated disorders. Methods: The safety of intravenous efgartigi…
View article: Supplementary Figures 1-7 from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Supplementary Figures 1-7 from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer Open
PDF file 415K, Supplementary Figures 1-7. Figure S1, related to Figure 1. Genome-wide siRNA screen identifies determinants of resistance to erlotinib treatment. Figure S2, related to Figure 2. Reduced Nf1 expression in erlotinib-resistant …
View article: Supplementary Text from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Supplementary Text from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer Open
PDF file 180K, Supplementary experimental procedures Supplementary table and figure legends Supplementary references
View article: Data from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Data from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer Open
Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib. However, resistance eventually arises, often due to a second EGFR mutati…
View article: Supplementary Text from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Supplementary Text from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer Open
PDF file 180K, Supplementary experimental procedures Supplementary table and figure legends Supplementary references
View article: Supplementary Table S4 from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Supplementary Table S4 from Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer Open
PDF file 108K, Table S4. Clinical characteristics of human lung adenocarcinoma samples